Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02RWC
|
|||
| Former ID |
DIB019925
|
|||
| Drug Name |
GNF-5837
|
|||
| Synonyms |
GNF 5837; GNF5837
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C28H21F4N5O2
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)C(=CC5=CC=CN5)C(=O)N4
|
|||
| InChI |
1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-
|
|||
| InChIKey |
YYDUWLSETXNJJT-MTJSOVHGSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | BDNF/NT-3 growth factors receptor (TrkB) | Target Info | Inhibitor | [1] |
| NT-3 growth factor receptor (TrkC) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Neurotrophin signaling pathway | ||||
| Alcoholism | ||||
| Pathway Interaction Database | SHP2 signaling | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | NGF-independant TRKA activation | |||
| ARMS-mediated activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| BDNF signaling pathway | ||||
| MAPK Signaling Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.